Skip to main content
Erschienen in: International Urogynecology Journal 6/2018

24.08.2017 | Original Article

Natural history of pelvic organ prolapse in symptomatic patients actively seeking treatment

verfasst von: Javier Pizarro-Berdichevsky, Ali Borazjani, Alejandro Pattillo, Marco Arellano, Jianbo Li, Howard B Goldman

Erschienen in: International Urogynecology Journal | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

At our institution many symptomatic patients must wait months or years for surgery. Our aim was to determine the rates of clinically significant pelvic organ prolapse (POP) progression and identify risk factors associated with POP progression.

Methods

Data from a prospectively maintained database of POP patients evaluated between 2008 and 2013 were analyzed. Women with symptomatic POP and two or more POP-Q examinations prior to surgery were included. POP progression was defined as having any of the POP-Q points Aa, Ba, C, D, Ap or Bp above the hymen at the baseline examination and at or below the hymen at the follow-up examination. Multivariable logistic analysis was preformed and the results are presented as odds ratios (OR) with 95% confidence intervals (CI).

Results

Of consecutive patients evaluated between July 2008 and June 2013, 388 met the inclusion criteria and were included. The median time between the POP-Q examinations was 9.9 months (IQR 7.8 to 13.8 months). The POP progression rate was 29.1% (95% CI 24.6–33.6%). Predictors of progression included age (OR 1.7, 95% CI 1.01–2.87) and the baseline status of points Ba, C, Bp and gH (OR 1.91, 95% CI 1.01–3.62; OR 0.53, 95% CI 0.3–0.94; OR 0.54, 95% CI 0.32–0.93; OR 2.15, 95% CI 1.13–4.1; respectively). POP-Q point correlations showed that anterior and posterior compartment points evolve with apical compartment points and gH evolves with both the anterior compartment and the apex.

Conclusions

Up to 29.1% of symptomatic patients with POP showed clinically significant progression over a median follow-up of 9.9 months. The likelihood of progression was not significantly associated with time. Those ≥60 years of age as well as those with point Ba ≥4 cm or gH ≥5 cm at baseline were at increased risk of POP progression.
Literatur
4.
Zurück zum Zitat Bland DR, Earle BB, Vitolins MZ, Burke G. Use of the Pelvic Organ Prolapse staging system of the International Continence Society, American Urogynecologic Society, and Society of Gynecologic Surgeons in perimenopausal women. Am J Obstet Gynecol. 1999;181(6):1324–7; discussion 1327–8. Bland DR, Earle BB, Vitolins MZ, Burke G. Use of the Pelvic Organ Prolapse staging system of the International Continence Society, American Urogynecologic Society, and Society of Gynecologic Surgeons in perimenopausal women. Am J Obstet Gynecol. 1999;181(6):1324–7; discussion 1327–8.
10.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.
11.
Zurück zum Zitat Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175(1):10–7. Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JO, Klarskov P, et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol. 1996;175(1):10–7.
13.
Zurück zum Zitat Flores-Espinoza C, Araya AX, Pizarro-Berdichevsky J, Santos V, Ferrer M, Garin O, et al. Validation of the Spanish-language version of the Prolapse Quality of Life questionnaire in Chilean women. Int Urogynecol J. 2015;26(1):123–30. https://doi.org/10.1007/s00192-014-2484-9. Flores-Espinoza C, Araya AX, Pizarro-Berdichevsky J, Santos V, Ferrer M, Garin O, et al. Validation of the Spanish-language version of the Prolapse Quality of Life questionnaire in Chilean women. Int Urogynecol J. 2015;26(1):123–30. https://​doi.​org/​10.​1007/​s00192-014-2484-9.
16.
Zurück zum Zitat Barber MD. Symptoms and outcome measures of pelvic organ prolapse. Clin Obstet Gynecol. 2005;48(3):648–61.CrossRefPubMed Barber MD. Symptoms and outcome measures of pelvic organ prolapse. Clin Obstet Gynecol. 2005;48(3):648–61.CrossRefPubMed
19.
Zurück zum Zitat Swift SE, Tate SB, Nicholas J. Correlation of symptoms with degree of pelvic organ support in a general population of women: what is pelvic organ prolapse? Am J Obstet Gynecol. 2003;189(2):372–7. discussion 377–9 Swift SE, Tate SB, Nicholas J. Correlation of symptoms with degree of pelvic organ support in a general population of women: what is pelvic organ prolapse? Am J Obstet Gynecol. 2003;189(2):372–7. discussion 377–9
Metadaten
Titel
Natural history of pelvic organ prolapse in symptomatic patients actively seeking treatment
verfasst von
Javier Pizarro-Berdichevsky
Ali Borazjani
Alejandro Pattillo
Marco Arellano
Jianbo Li
Howard B Goldman
Publikationsdatum
24.08.2017
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 6/2018
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-017-3450-0

Weitere Artikel der Ausgabe 6/2018

International Urogynecology Journal 6/2018 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.